Alexion Pharmaceuticals Inc. Reports Positive Interim Safety And Efficacy Results For Soliris(TM) (eculizumab) From The Open-Label Phase III SHEPHERD Safety Trial In Paroxysmal Nocturnal Hemoglobinuria Patients

CHESHIRE, Conn., June 12 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN - News) today reported positive preliminary six month interim results from SHEPHERD, its second Phase III trial testing Soliris(TM) (eculizumab) in a broader population of Paroxysmal Nocturnal Hemoglobinuria (“PNH”) patients. SHEPHERD is an open-label, non-placebo controlled 12 month Phase III PNH study which is primarily focused on examining safety, as well as efficacy measures. Interim results show that Soliris(TM) (eculizumab) appeared to be safe and well tolerated.